Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 4
Submit an article Journal homepage
1,825
Views
21
CrossRef citations to date
0
Altmetric
Original Research

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment

Dang-Nghiem VoINSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, France;Institute for Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier, FranceView further author information
,
Catherine AlexiaINSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, FranceView further author information
,
Nerea Allende-VegaINSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, France;Institute for Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier, FranceView further author information
,
Franck MorschhauserUniv. Lille, CHU Lille, EA 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, FranceView further author information
,
Roch HouotDepartment of Clinical Hematology, University Hospital Rennes, Rennes, France;UMR U1236, INSERM Université Rennes 1, Etablissement Français du Sang, Rennes, FranceView further author information
,
Cedric MenardUMR U1236, INSERM Université Rennes 1, Etablissement Français du Sang, Rennes, France;SITI, Pôle de Biologie, CHU de Rennes, Rennes, FranceView further author information
,
Karin TarteUMR U1236, INSERM Université Rennes 1, Etablissement Français du Sang, Rennes, France;SITI, Pôle de Biologie, CHU de Rennes, Rennes, FranceView further author information
,
Guillaume CartronDépartement d'Hématologie Clinique, CHU Montpellier, Université Montpellier I, 80 avenue Augustin Fliche, Montpellier, France;CNRS UMR5235, Université de Montpellier, Montpellier, FranceView further author information
&
Martin VillalbaINSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, France;Institute for Regenerative Medicine and Biotherapy (IRMB), CHU Montpellier, Montpellier, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4385-4888View further author information
ORCID Icon show all
Article: e1409322 | Received 29 Sep 2017, Accepted 20 Nov 2017, Published online: 20 Dec 2017

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Melody Smith, Elena García-Martínez, Michael R. Pitter, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Toll-like receptor agonists in cancer immunotherapy. OncoImmunology 7:12.
Read now

Articles from other publishers (20)

Yago Nieto, Pinaki Banerjee, Indresh Kaur, Kun Hee Kim, Dexing Fang, Peter F Thall, Lori Griffin, Melissa Barnett, Rafet Basar, Chitra Hosing, Jeremy Ramdial, Samer Srour, May Daher, David Marin, Xianli Jiang, Ken Chen, Richard Champlin, Elizabeth J Shpall & Katayoun Rezvani. (2023) EX VIVO-EXPANDED CORD BLOOD NK CELLS COMBINED WITH RITUXIMAB AND HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS SCT FOR B-NHL. Transplantation and Cellular Therapy.
Crossref
Hua-Jay J. Cherng, Stefan K. Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F. M. Craig, Charles W. Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J. McDonnell, Christopher R. Flowers, Francisco Vega, Michael R. Green, Lei Feng, David M. Kurtz, Ash A. Alizadeh, R. Eric Davis & Jason R. Westin. (2023) A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances 7:7, pages 1137-1145.
Crossref
Elizabeth Smyth, Chan Y. Cheah & John F. Seymour. (2023) Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies. Cancer Treatment Reviews 113, pages 102510.
Crossref
Jing He, Ziwei Chen, Qingfeng Xue, Pingping Sun, Yuan Wang, Cindy Zhu & Wenyu Shi. (2022) Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature. Journal of Translational Medicine 20:1.
Crossref
Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro & Dennis Huszar. (2022) The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood 139:18, pages 2770-2781.
Crossref
Dang-Nghiem Vo, Nicolas Leventoux, Mauricio Campos-Mora, Sandrine Gimenez, Pierre Corbeau & Martin Villalba. (2022) NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1. Vaccines 10:5, pages 688.
Crossref
David Qualls & Gilles Salles. (2022) Prospects in the management of patients with follicular lymphoma beyond first-line therapy. Haematologica 107:1, pages 19-34.
Crossref
Cédric Ménard, Delphine Rossille, Joelle Dulong, Tien-Tuan Nguyen, Ilenia PapaMaelle Latour, Nadège Bescher, Isabelle Bezier, Myriam Chouteau, Thierry Fest, Roch Houot, Franck Morschhauser & Karin Tarte. (2021) Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Advances 5:8, pages 2063-2074.
Crossref
Johannes Düll, Max Topp & Gilles Salles. (2021) The use of tafasitamab in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology 12, pages 204062072110274.
Crossref
Dang-Nghiem Vo, Michael Constantinides, Nerea Allende-Vega, Catherine Alexia, Guillaume Cartron & Martin Villalba. (2020) Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function. Vaccines 8:4, pages 727.
Crossref
Tania Calvo, Chantal Reina-Ortiz, David Giraldos, María Gascón, Daniel Woods, Judit Asenjo, Joaquín Marco-Brualla, Gemma Azaceta, Isabel Izquierdo, Luis Palomera, Diego Sánchez-Martínez, Isabel Marzo, Javier Naval, Carlos Vilches, Martín Villalba & Alberto Anel. (2020) Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports 10:1.
Crossref
Hao Zhou, Chang Zheng & De-Sheng Huang. (2020) A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma. PeerJ 8, pages e9658.
Crossref
Loic Ysebaert & Franck Morschhauser. (2020) Immunomodulatory Agents in Follicular Lymphoma. Hematology/Oncology Clinics of North America 34:4, pages 715-726.
Crossref
Aviad Ben-Shmuel, Guy Biber & Mira Barda-Saad. (2020) Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology 11.
Crossref
Martin Villalba, Catherine Alexia, Anais Bellin-Robert, Alexis Fayd'herbe de Maudave & Delphine Gitenay. (2020) Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells. Frontiers in Immunology 10.
Crossref
Catherine Alexia, Mailys Cren, Pascale Louis-Plence, Dang-Nghiem Vo, Yasamine El Ahmadi, Emilie Dufourcq-Lopez, Zhao-Yang Lu, Javier Hernandez, Farkhad Shamilov, Olga Chernysheva, M. Vasilieva, I. Vorotnikov, Yana Vishnevskay, Nikolay Tupitsyn, Jean-François Rossi & Martin Villalba. (2019) Polyoxidonium® Activates Cytotoxic Lymphocyte Responses Through Dendritic Cell Maturation: Clinical Effects in Breast Cancer. Frontiers in Immunology 10.
Crossref
Gonzalez-Rodriguez, Villa-Álvarez, Sordo-Bahamonde, Lorenzo-Herrero & Gonzalez. (2019) NK Cells in the Treatment of Hematological Malignancies. Journal of Clinical Medicine 8:10, pages 1557.
Crossref
Franck Morschhauser, Steven Le Gouill, Pierre Feugier, Sarah Bailly, Emmanuelle Nicolas-Virelizier, Fontanet Bijou, Gilles A Salles, Hervé Tilly, Christophe Fruchart, Koen Van Eygen, Sylvia Snauwaert, Christophe Bonnet, Corinne Haioun, Catherine Thieblemont, Reda Bouabdallah, Ka Lung Wu, Danielle Canioni, Véronique Meignin, Guillaume Cartron & Roch Houot. (2019) Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. The Lancet Haematology 6:8, pages e429-e437.
Crossref
Hsiling Chiu, Preeti Trisal, Chad Bjorklund, Soraya Carrancio, Estela G. Toraño, Carla Guarinos, Despoina Papazoglou, Patrick R. Hagner, Asma Beldi‐Ferchiou, Karin Tarte, Marie‐Hélène Delfau‐Larue, Franck Morschhauser, Alan G. Ramsay & Anita K. Gandhi. (2019) Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. British Journal of Haematology 185:2, pages 240-253.
Crossref
Franck Morschhauser, Gilles SallesSteven Le GouillHerve TillyCatherine ThieblemontKrimo BouabdallahBettina FabianiCédric MénardKarin Tarte, Guillaume Cartron & Roch Houot. (2018) An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood 132:14, pages 1486-1494.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.